PharmaShots’ Most Read News of 2019

The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales promotion…

BySenior EditorJanuary 10, 2020

INSIGHTS+

Insights+: COVID-19 Healthcare News Monthly Updates – April 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

BySenior EditorJanuary 5, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2019

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year's record of approvals. However, there is a significant…

BySenior EditorDecember 13, 2019

INSIGHTS+

Insights+ Key Biosimilars Events of November 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar…

BySenior EditorDecember 6, 2019

INSIGHTS+

Insights+: The US FDA New Drug Approvals in September and October 2019

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year's record of approvals. However, there is a significant…

BySenior EditorNovember 15, 2019

VIEWPOINTS

PharmaShots Interview: AstraZeneca’s Global Medicine Leader John Houghton Shares Insights on Roxadustat in Treating Patients with Anemia Due to CKD at ASN 2019

AstraZeneca presented P-III data of Roxadustat along with unprecedented 41 abstracts from its renal portfolio at American Society of Nephrology Kidney Week 2019, demonstrating its commitment to advancing the care of Chronic Kidney Diseases (CKD) and its complications, affecting millions of people across the globe. On Nov 12, 2019 in an interview with PharmaShots, John…

BySenior EditorNovember 12, 2019

INSIGHTS+

Insights+ Key Biosimilars Events of October 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics'possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the biosimilar…

BySenior EditorNovember 1, 2019

INSIGHTS+

Insights+ Key Biosimilars Events of September 2019

Biosimilars are key alternatives for costly Biologics therapies and saving millions of dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of the…

BySenior EditorOctober 4, 2019

INSIGHTS+

Insights+: The US FDA New Drug Approvals in August 2019

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 31 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entity and 17 Biologics while breaking its past year's records of approval. However, there is a significant…

BySenior EditorSeptember 20, 2019

INSIGHTS+

Insights+ Key Biosimilars Events of August 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of biosimilar space…

BySenior EditorSeptember 9, 2019

Senior Editor

PharmaShots’ Most Read News of 2019

Insights+: COVID-19 Healthcare News Monthly Updates – April 2020

Insights+: The US FDA New Drug Approvals in November 2019

Insights+ Key Biosimilars Events of November 2019

Insights+: The US FDA New Drug Approvals in September and October 2019

PharmaShots Interview: AstraZeneca’s Global Medicine Leader John Houghton Shares Insights on Roxadustat in Treating Patients with Anemia Due to CKD at ASN 2019

Insights+ Key Biosimilars Events of October 2019

Insights+ Key Biosimilars Events of September 2019

Insights+: The US FDA New Drug Approvals in August 2019

Insights+ Key Biosimilars Events of August 2019

Contact US

FOLLOW US